Exp Neurobiol 2020; 29(2): 138-149
Published online April 30, 2020
© The Korean Society for Brain and Neural Sciences
Ting-Wei Mi1,2†, Xiao-Wen Sun1,3†, Zhi-Meng Wang1,3†, Ying-Ying Wang1,3†, Xuan-Cheng He1,2†, Cong Liu1,3, Shuang-Feng Zhang1,4, Hong-Zhen Du1,2, Chang-Mei Liu1,2,3* and Zhao-Qian Teng1,2,3*
1State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing 100101, 2Institute for Stem Cell and Regeneration, Chinese Academy of Sciences, Beijing 100101, 3Savaid Medical School, University of Chinese Academy of Sciences, Beijing 100049, 4School of Life Sciences, University of Science and Technology of China, Hefei 230026, China
Correspondence to: *To whom correspondence should be addressed.
Zhao-Qian Teng, TEL: 86-10-82619699, FAX: 86-10-64807099
Chang-Mei Liu, TEL: 86-10-82619690, FAX: 86-10-64807316
†These authors equally contributed to this work.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License
(http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Neuropsychiatric disorders are the leading cause of mental and intellectual disabilities worldwide. Current therapies against neuropsychiatric disorders are very limited, and very little is known about the onset and development of these diseases, and their most effective treatments.